Current Cardiology Reports

, 9:406 | Cite as

The risk of drug-eluting stent thrombosis with noncardiac surgery

  • Emmanouil S. Brilakis
  • Subhash Banerjee
  • Peter B. Berger
Inverventional Cardiology


Patients in whom any kind of stent, particularly a drug-eluting stent (DES), was recently implanted are at risk for stent thrombosis when they undergo noncardiac surgery, even months or years after their implantation. The risk of DES thrombosis is likely decreased by delaying noncardiac surgery for as long as possible and continuing dual or at least single antiplatelet therapy in the perioperative period. Preoperative identification and close monitoring of patients with DES may allow prevention and prompt detection and treatment of this catastrophic complication.


Clopidogrel Antiplatelet Therapy Bivalirudin Dual Antiplatelet Therapy Noncardiac Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Kaluza GL, Joseph J, Lee JR, et al.:Catastrophic outcomes of noncardiac surgery soon after coronary stenting.J Am Coll Cardiol 2000,35:1288–1294.PubMedCrossRefGoogle Scholar
  2. 2.
    Wilson SH, Fasseas P, Orford JL, et al.:Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.J Am Coll Cardiol 2003,42:234–240.PubMedCrossRefGoogle Scholar
  3. 3.
    Sharma AK, Ajani AE, Hamwi SM, et al.:Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Intery 2004,63:141–145.CrossRefGoogle Scholar
  4. 4.
    Reddy PR, Vaitkus PT:Risks of noncardiac surgery after coronary stenting.Am J Cardiol 2005,95:755–757.PubMedCrossRefGoogle Scholar
  5. 5.
    Schouten O, Domburg RTV, Bax JJ, et al.:Cardiac outcome after noncardiac surgery in patients with recent coronary stenting.Eur Heart J 2006,27(Suppl 1):86.Google Scholar
  6. 6.
    Kim HL, Park KW, Kwak JJ, et al.:Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent.Int J Cardiol 2007 [epub ahead of print].Google Scholar
  7. 7.
    Iakovou I, Schmidt T, Bonizzoni E, et al.:Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA 2005,293:2126–2130.PubMedCrossRefGoogle Scholar
  8. 8.
    Daemen J, Wenaweser P, Tsuchida K, et al.:Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.Lancet 2007,369:667–678.PubMedCrossRefGoogle Scholar
  9. 9.
    Of importance Schouten O, van Domburg RT, Bax JJ, et al.:Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events.J Am Coll Cardiol 2007,49:122–124. One of the largest series of patients who underwent noncardiac surgery after DES implantation. The highest risk for stent thrombosis and cardiac complications was when surgery was performed early after stenting and when antiplatelet therapy was withheld.PubMedCrossRefGoogle Scholar
  10. 10.
    Marcucci C, Chassot PG, Gardaz JP, et al.:Fatal myocardial infarction after lung resection in a patient with prophylactic preoperative coronary stenting.Br J Anaesth 2004,92:743–747.PubMedCrossRefGoogle Scholar
  11. 11.
    Eagle KA, Berger PB, Calkins H, et al.:ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).Circulation 2002,105:1257–1267.PubMedGoogle Scholar
  12. 12.
    McFadden EP, Stabile E, Regar E, et al.:Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.Lancet 2004,364:1519–1521.PubMedCrossRefGoogle Scholar
  13. 13.
    Ong AT, McFadden EP, Regar E, et al.:Late angiographic stent thrombosis (LAST) events with drug-eluting stents.J Am Coll Cardiol 2005,45:2088–2092.PubMedCrossRefGoogle Scholar
  14. 14.
    Nasser M, Kapeliovich M, Markiewicz W:Late thrombosis of sirolimus-eluting stents following noncardiac surgery.Catheter Cardiovasc Interv 2005,65:516–519.PubMedCrossRefGoogle Scholar
  15. 15.
    Compton PA, Zankar AA, Adesanya AO, et al.:Risk of noncardiac surgery after coronary drug-eluting stent implantation.Am J Cardiol 2006,98:1212–1213.PubMedCrossRefGoogle Scholar
  16. 16.
    Bakhru M, Saber W, Brotman D, et al.:Is discontinuation of antiplatelet therapy after 6 months safe in patients with drug-eluting stents undergoing noncardiac surgery? Cleve Clin J Med 2006,73:S23.Google Scholar
  17. 17.
    Hausleiter J, Kastrati A, Mehilli J, et al.:Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries.J Am Coll Cardiol 2002,40:882–889.PubMedCrossRefGoogle Scholar
  18. 18.
    Mehilli J, Dibra A, Kastrati A, et al.:Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.Eur Heart J 2006,27:260–266.PubMedCrossRefGoogle Scholar
  19. 19.
    Ardissino D, Cavallini C, Bramucci E, et al.:Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.JAMA 2004,292:2727–2734.PubMedCrossRefGoogle Scholar
  20. 20.
    Moreno R, Fernandez C, Hernandez R, et al.:Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.J Am Coll Cardiol 2005,45:954–959.PubMedCrossRefGoogle Scholar
  21. 21.
    Orford JL, Lennon R, Melby S, et al.:Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.J Am Coll Cardiol 2002,40:1567–1572.PubMedCrossRefGoogle Scholar
  22. 22.
    Cutlip DE, Baim DS, Ho KK, et al.:Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.Circulation 2001,103:1967–1971.PubMedGoogle Scholar
  23. 23.
    Fujii K, Carlier SG, Mintz GS, et al.:Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study.J Am Coll Cardiol 2005,45:995–998.PubMedCrossRefGoogle Scholar
  24. 24.
    Cheneau E, Leborgne L, Mintz GS, et al.:Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study.Circulation 2003,108:43–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Regar E, Lemos PA, Saia F, et al.:Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients.Am J Cardiol 2005,93:1271–1275.CrossRefGoogle Scholar
  26. 26.
    Ong AT, Hoye A, Aoki J, et al.:Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.J Am Coll Cardiol 2005,45:947–953.PubMedCrossRefGoogle Scholar
  27. 27.
    Luscher TF, Steffel J, Eberli FR, et al.:Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.Circulation 2007,115:1051–1058.PubMedCrossRefGoogle Scholar
  28. 28.
    Kotani J, Awata M, Nanto S, et al.:Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.J Am Coll Cardiol 2006,47:2108–2111.PubMedCrossRefGoogle Scholar
  29. 29.
    Matsumoto D, Shite J, Shinke T, et al.:Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.Eur Heart J 2007,28:961–967.PubMedCrossRefGoogle Scholar
  30. 30.
    Finn AV, Kolodgie FD, Harnek J, et al.:Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.Circulation 2005,112:270–278.PubMedCrossRefGoogle Scholar
  31. 31.
    Sautter RD, Myers WO, Ray JF 3rd, Wenzel FJ:Relationship of fibrinolytic system to postoperative thrombotic phenomena.Arch Surg 1973,107:292–296.PubMedGoogle Scholar
  32. 32.
    Sametz W, Metzler H, Gries M, et al.:Perioperative catecholamine changes in cardiac risk patients.Eur J Clin Invest 1999,29:582–587.PubMedCrossRefGoogle Scholar
  33. 33.
    Of importance Grines CL, Bonow RO, Casey DE Jr, et al.:Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.J Am Coll Cardiol 2007,49:734–739. Consensus statement providing practical recommendations about how to manage the antiplatelet regimen of patients receiving DES. Delaying surgery for at least 12 months after DES implantation is recommended.PubMedCrossRefGoogle Scholar
  34. 34.
    Of major importance McFalls EO, Ward HB, Moritz TE, et al.:Coronary-artery revascularization before elective major vascular surgery.N Engl J Med 2004,351:2795–2804. A landmark randomized trial of preoperative coronary revascularization versus medical therapy alone in patients with stable coronary artery disease undergoing major vascular surgery revealed that there was no short- or long-term benefit derived from coronary revascularization.PubMedCrossRefGoogle Scholar
  35. 35.
    Ward HB, Kelly RF, Thottapurathu L, et al.:Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery.Ann Thorac Surg 2006,82:795–800; discussion 800–801.PubMedCrossRefGoogle Scholar
  36. 36.
    Poldermans D, Bax JJ, Schouten O, et al.:Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006,48:964–969.PubMedCrossRefGoogle Scholar
  37. 37.
    Poldermans D, Schouten O, Vidakovic R, et al.:A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study.J Am Coll Cardiol 2007,49:1763–1769.PubMedCrossRefGoogle Scholar
  38. 38.
    Brilakis ES, Orford JL, Fasseas P, et al.:Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery.Am J Cardiol 2005,96:512–514.PubMedCrossRefGoogle Scholar
  39. 39.
    Holmes DR, Jr, Teirstein P, Satler L, et al.: for the SISR Investigators:Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.JAMA 2006,295:1264–1273.PubMedCrossRefGoogle Scholar
  40. 40.
    Stone GW, Ellis SG, O’Shaughnessy CD, et al.: for the TAXUS V ISR Investigators:Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within baremetal stents: the TAXUS V ISR randomized trial.JAMA 2006,295:1253–1263.PubMedCrossRefGoogle Scholar
  41. 41.
    Valerin M, Brennan M, Noll J, et al.:Relationship between aspirin use and postoperative bleeding from dental extractions in a healthy population.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006,102:326.CrossRefGoogle Scholar
  42. 42.
    Ernst A, Eberhardt R, Wahidi M, et al.:Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans.Chest 2006,129:734–737.PubMedCrossRefGoogle Scholar
  43. 43.
    Kumar N, Jivan S, Thomas P, et al.:Sub-Tenon’s anesthesia with aspirin, warfarin, and clopidogrel.J Cataract Refract Surg 2006,32:1022–1025.PubMedCrossRefGoogle Scholar
  44. 44.
    Alam M, Goldberg LH:Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.Dermatol Surg 2002,28:992–998. discussion 998.PubMedCrossRefGoogle Scholar
  45. 45.
    Dupuis JY, Labinaz M:Noncardiac surgery in patients with coronary artery stent: what should the anesthesiologist know? Can J Anaesth 2005,52:356–361.PubMedGoogle Scholar
  46. 46.
    Jaffe R, Halon DA, Carmeli J, Lewis BS:Prolonged intravenous epitifibatide infusion for prevention of coronary stent thrombosis.Int J Cardiol 2007,114:409–411.PubMedCrossRefGoogle Scholar
  47. 47.
    Di Nisio M, Bijsterveld NR, Meijers JC, et al.:Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.J Am Coll Cardiol 2005,46:1582–1583.PubMedCrossRefGoogle Scholar
  48. 48.
    Mauri L, Hsieh WH, Massaro JM, et al.:Stent thrombosis in randomized clinical trials of drug-eluting stents.N Engl J Med 2007,356:1020–1029.PubMedCrossRefGoogle Scholar
  49. 49.
    Stone GW, Moses JW, Ellis SG, et al.:Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.N Engl J Med 2007,356:998–1008.PubMedCrossRefGoogle Scholar
  50. 50.
    Lagerqvist B, James SK, Stenestrand U, et al.:Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.N Engl J Med 2007,356:1009–1019.PubMedCrossRefGoogle Scholar
  51. 51.
    Patterson L, Hunter D, Mann A:Appropriate waiting time for noncardiac surgery following coronary stent insertion: views of Canadian anesthesiologists.Can J Anaesth 2005,52:440–441.PubMedCrossRefGoogle Scholar
  52. 52.
    Adesanya AO, de Lemos JA, Greilich NB, Whitten CW:Management of perioperative myocardial infarction in noncardiac surgical patients.Chest 2006,130:584–596.PubMedCrossRefGoogle Scholar
  53. 53.
    Berger PB, Bellot V, Bell MR, et al.:An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery.Am J Cardiol 2001,87:1100–1102.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Emmanouil S. Brilakis
    • 1
  • Subhash Banerjee
  • Peter B. Berger
  1. 1.Dallas VA Medical Center (111A)DallasUSA

Personalised recommendations